Medical therapies are an important treatment option, particularly for patients who may not be suitable for surgery or those with persistently high levels of GH/IGF1 following surgery
Pharmacokinetic profiles for the compound place its plasma half-life in the neighborhood of 45 minutes after parenteral administration in animal models, which informs typical dosing intervals in published experiments
Useful for trial participants and anyone planning a future protocol
Taking a GLP-1 injection slightly early is generally not harmful, but doses given too close together may increase the risk of side effects such as nausea, vomiting, or abdominal discomfort
Because Semaglutide directly affects metabolism and appetite regulation, careful medical monitoring is essential
In our cohort, treatment with semaglutide reduced median body weight by 1.3 kg and 2.9 kg over 3 and 6 months, respectively